Navigation Links
Blood Pressure Control in Middle Age Can Lower Lifetime Heart Risk
Date:12/19/2011

MONDAY, Dec. 19 (HealthDay News) -- Blood pressure changes in middle age can affect your lifetime risk for heart disease and stroke, a new study suggests.

U.S. researchers analyzed data from almost 62,000 people whose blood pressure readings were tracked for an average of 14 years.

People who kept or lowered their blood pressure to normal levels by age 55 had the lowest lifetime risk (22 percent to 41 percent) for heart disease. The risk for people who had high blood pressure at age 55, however, was 42 percent to 69 percent.

When all blood pressure levels were factored in, the overall lifetime heart disease risk for people over the age of 55 was about 53 percent for men and about 40 percent for women.

"This study adds to our existing knowledge that hypertension is the most important modifiable risk factor for cardiovascular disease, including coronary heart disease and stroke," said expert Dr. Robert Graham, an internist at Lenox Hill Hospital in New York City. "Unfortunately, many patients do not take this 'silent disease' seriously because they usually don't see or feel the effects of their hypertension until some catastrophic outcome has occurred," he added.

Among the other findings:

  • Women generally had higher increases in middle age than men, and women who have high blood pressure by early middle age (average age 41) have a higher lifetime risk for heart disease (49 percent) than those who have maintained normal blood pressure up to age 55.
  • At an average age of 55, 26 percent of men had normal blood pressure, as did 41 percent of women, while about 49 percent of men and 48 percent of women had prehypertension.
  • Nearly 70 percent of men who develop high blood pressure in middle age will experience a cardiovascular event such as a stroke or heart attack by age 85, the team found.

The study appears Dec. 19 in the journal Circulation.

"Taking blood pressure changes into account can provide more accurate estimates for lifetime risk of cardiovascular disease, and it can help us predict individualized risk, and thus, individualized prevention strategies," study author Norrina Allen, an assistant professor in the department of preventive medicine at the Northwestern University Feinberg School of Medicine, in Chicago, explained in a journal news release.

"Both avoiding hypertension during middle age or delaying the onset of the development of hypertension appear to have a significant impact on an individual's remaining lifetime risk for CVD," Allen noted.

Graham agreed. He said that hypertension in middle age "can affect one's lifetime risk for heart disease and stroke. Fortunately, with medications and lifestyle changes, patients who control their blood pressure during middle age had the lowest lifetime risk of cardiovascular disease, while those with an increase in blood pressure had the highest risk."

More information

The U.S. National Heart, Lung, and Blood Institute offers a guide to lowering high blood pressure.

-- Robert Preidt

SOURCE: Robert Graham, M.D., internist, Lenox Hill Hospital, New York City; Circulation, news release, Dec. 15, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Brief, Intense Exercise Lowers Blood Sugar, Small Study Finds
2. Less blood needed post-surgery, says NEJM study
3. Team designs a bandage that spurs, guides blood vessel growth
4. Blood test might predict how well a depressed patient responds to antidepressants
5. Low Iron Levels May Increase Blood Clot Risk
6. Key genetic error found in family of blood cancers
7. University of Maryland finds restricting post-surgery blood transfusion is safe for some hip patients
8. Study Finds Fewer Blood Transfusions Needed After Hip Surgeries
9. Cancer Outpatients at Greater Risk for Blood Clots
10. Bone marrow and blood stem cell transplant survival rates equal, when donor is unrelated to patient
11. Massive DNA search uncovers new mutations driving blood cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Blood Pressure Control in Middle Age Can Lower Lifetime Heart Risk
(Date:2/22/2017)... ... February 22, 2017 , ... ... newest advanced absorption cannabidiol (CBD) serum, “NANOCALM 300” Microemulsified Hemp Extract. This ... instant absorption from the mouth into the bloodstream. Far outpacing the ...
(Date:2/22/2017)... ... 22, 2017 , ... The Centers for Medicare & Medicaid ... in Delaware, New Jersey, Pennsylvania and West Virginia prepare for and participate in ... Act of 2015 (MACRA). , This technical assistance, authorized and funded under ...
(Date:2/22/2017)... NJ (PRWEB) , ... February 22, 2017 , ... ... healthcare communications company, launched a new media platform connecting healthcare technology professionals and ... will be followed by a quarterly publication starting on March 1, announced Michael ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pet obesity in the U.S. continued ... according to the Association for Pet Obesity Prevention (APOP). During the ninth annual survey, ... such as the benefits of corn and grains, value of raw and organic diets, ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... so many different solutions on the market, it is easy to start feeling ... Premier Locksmith offers a complimentary security consultation. , Home Security Hardware Choices, ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... , Feb. 22, 2017 Henry ... an exclusive distribution agreement with Rijuven, which develops ... diagnostic device to medical practitioners. ... electrocardiogram (ECG) and heart sound signals, transmits real-time ... and offers cloud-based analysis to help physicians provide ...
(Date:2/22/2017)... Calif. , Feb. 22, 2017  Bioness, Inc., ... therapies, today announced the first series of successful StimRouter ... at Radboud University Medical Center (Nijmegen, Netherlands ... ( Cork, Ireland ), and Kliniek Park ... the successful launch continuing, Bioness plans to further support ...
(Date:2/22/2017)... , Feb. 22, 2017 Oncternal Therapeutics, ... for both rare and common malignancies, today announced ... financing. The company intends to use the proceeds ... TK216, and to advance preclinical development of a ... Cirmtuzumab is a first-in-class anti-ROR1 monoclonal antibody being ...
Breaking Medicine Technology: